BioNTech sees FY23 Covid-19 vaccine revenue ~EUR 5B

This revenue estimate reflects expected revenues related to BioNTech’s (BNTX) share of gross profit from COVID-19 vaccine sales in the collaboration partner’s territories, from direct COVID-19 vaccine sales to customers in BioNTech’s territory and expected revenues from sales to collaboration partners which may be influenced by costs like inventory write-offs once materialized and shared with the collaboration partner Pfizer (PFE).